Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9Y5X4
UPID:
NR2E3_HUMAN
Alternative names:
Nuclear receptor subfamily 2 group E member 3; Retina-specific nuclear receptor
Alternative UPACC:
Q9Y5X4; B6ZGU0; Q9UHM4
Background:
The Photoreceptor-specific nuclear receptor, also known as Nuclear receptor subfamily 2 group E member 3, plays a pivotal role in retinal photoreceptor cells. It acts as a transcriptional factor, promoting rod development while inhibiting cone development, and regulates the expression of genes critical for vision, including rhodopsin and opsins.
Therapeutic significance:
Linked to Enhanced S cone syndrome and Retinitis pigmentosa 37, this protein's understanding could pave the way for innovative treatments targeting these retinal dystrophies, potentially restoring or preserving vision.